<i>In vitro</i> activities of contezolid (MRX-I) against drug-sensitive and drug-resistant <i>Mycobacterium tuberculosis</i>

Importance Currently, Mycobacterium tuberculosis has exhibited increased drug resistance, leading to ineffective drug treatment in many patients with tuberculosis. Among the anti- Mycobacterium tuberculosis drugs, oxazolidinones have been gradually developed. Contezolid (MRX-I) has been newly developed in China with advantages versus the first oxazolidinone antibiotic approved by the Food and Drug Administration for clinical use, but the anti- M. tuberculosis activity needs to be further clarified. In this study, in vitro activities of MRX-I against M. tuberculosis were tested. The drug susceptibility assays indicated that MRX-I exhibited anti- M. tuberculosis activity comparable to that of linezolid, with an advantage against drug-resistant isolates.